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FLUPHENAZINE DECANOATE IN CHRONIC SCHIZOPHRENIA 
G. D. SHUKLA,
1 M.D. 
Introduction of chlorpromazine by 
Delay and Danikcr in 1952 revolutionized 
the treatment of acute schizophrenia. How-
ever, chronic form of the illness still remains 
a challenge, mainly because of non-
compliance of the patients with the thera-
peutic regimen (Diamond and Marks, 1960; 
Olson and Peterson, 1960; Hare and 
Willcox, 1967 ; Wilson and Enoch, 1967 
and Ayd, 1975). Another factor is the 
erratic absorption of neuroleptics in these 
cases (Lewis et al., 1971). Long acting 
phenothiazines were developed to overcome 
these problems. Fluphenazine enanthate, 
probably the first such preparation, though 
useful in chronic schizophrenia, had a 
rather short (1-2 weeks) duration of action 
and marked extrapyramidal effects (Miller 
and Daniel, 1967; Shah et al., 1971 and 
Bagadia et al., 1972). 
Fluphenazine decanoate, a newer pro-
duct, has been claimed to produce less 
extrapyramidal effects and has an action 
lasting for 3-4 weeks (Falton et al., 1978 
and Silverstone and Turner, 1978). There 
are still rather few reports on its efficacy 
and safety-particularly from our country 
(Gahlot et al., 1977 and Bagadia et al., 
1979). Further, these reports have been of 
rather short duration—lasting over 4-5 
months only—thus making it difficult to 
assess the efficacy of the drug in an illness 
continuing over years with unpredictably 
fluctuating course. This presentation, there-
fore, aims at reporting the results of a long 
term (1 -3 years) trial of the drug in a group 
of chronic schizophrenics. 
MATERIAL AND METHODS 
College, Jhansi from July 1977 to June 1980. 
Schizophrenics with illness lasting for two 
years or more, with no or incomplete 
recovery and frequent relapses despite treat-
ment with oral neuroleptics and/or E.C.T. 
were included in the trial. A detailed 
history taking and thorough mental status 
examination were carried out to have a 
baseline record for future comparison. Flu-
phenazine decanoate (Anatensol decanoate) 
was administered intramuscularly in the 
dose of 25 mg. at intervals of three weeks. 
No other neuroleptic was given. As far 
as possible, the patients were hospitalized 
for the first injection to observe untoward 
effects, if any. Antiparkinsonian medication 
(Trihexyphenidyl or Procyclidine) was 
started only if the patient developed extra-
pyramidal effects. These drugs, if needed, 
were given only for up to 10 days following 
every injection. Acute dystonic reactions 
were managed with intramuscular prome-
thazine (Phenargan). 
The patients were checked and injection 
was given at intervals of three weeks. Dur-
ing every visit, the progress was recorded with 
respect to salient clinical features, general ad-
justment and side effects—taking into account 
the findings of examination and the report 
of a reliable relative. A 'good response' 
meant an improvement in general behaviour 
to the near normal level, disappearance of 
symptoms like excitement, thought disorder, 
delusions, hallucinations and emotional in-
appropriateness. Patients with partial or 
no improvement were rated as showing 
'poor or no response'. 
RFSULTS 
The study was carried out in the Out of 65 cases taken up for the trial, 
Psychiatric Clinic of M. L. B. Medical 25 (38.5%) had to be excluded from analysi* 
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because they did not come regularly for 
assessment and/or injections. In six of 
these, injections had to be discontinued 
because of side effects in form of restlessness, 
anxiety and dystonia. Antiparkinsonian 
medication had no effect in these cases. 
Even reduction of the dose to half did not 
help. The analysis henceforth will be 
limited to the remaining 40 (61.5%) cases 
who came regularly for follow up and 
injections. 
Therapy was found to be markedly 
effective in nearly two third of cases (25, 
62.5%) while the rest (15, 37.5%) showed 
poor or no response (Table I). In general, 
the response was better in cases with onset 
of illness after the age of 20 years. Two 
thirds, half and all the cases in the age 
groups 20-40, 40-50 and beyond 50 res-
pectively, showed good response. On the 
other hand, only 25% of the cases below 
20 years had good response. The response 
TABLE I—Showing the variables of duration 
of illness, type of schizophrenia and duration 
of follow up of patients showing good response* 
Variable 
(a) Duration of illness \ 
2—5 
5—10 
10—15 
15—20 
Number of 
cases 
(N=40) 
jit years): 
27 
8 
3 
2 
(6) Type of Schizophrenia: 
Simple 
Hebephrenic 
Catatonic 
Paranoid 
4 
12 
6 
11 
Undifferentia ted 7 
(c) Duration of follow 
3 
2 
1 
up (in years): 
8 
15 
17 
No- with good 
response 
(N=25j 
19 (70.4) 
4 (50.0) 
1 (33.3) 
1 (50.0) 
1 (25.0) 
5 (41.6) 
4 (66.6) 
8 (72.5) 
5 (71.4) 
5 (62.5) 
9 (60.0) 
11 (64.7) 
was almost equal in the two sexes, 62.9% 
and 61.5% of males and females respectively, 
showed a good response. 
The response was best in cases with 
illness lasting 2-5 years beyond which it 
declined with increasing duration of the 
disease. While 70.4% of cases with 2-5 
years showed a good response, only 50.0% 
or less of those with a longer duration did 
so. Cases with paranoid and undifferentiated 
forms of illness had best response, nearly 
70% showing marked improvement. Two 
thirds (66.6%) of catatonics shewed good 
response while habephrenics and simple 
schizophrenics did worse, only 41.6% and 
25.0% respectively, showing good response. 
The response to the drug was sustained over 
the period of study, there being almost 
equal response in patients followed up for 
3, 2 and 1 year (Table I). 
Side effects encountered have been 
listed in Table II. The commonest was 
parkinsonism in the form of tremors and 
rigidity (22, 55.0%). Dystonia occurred 
in 8(20.0%) cases while akathesia was 
seen in 11 (27.0%). All these could be 
ameliorated by antiparkinsonian medication 
which was needed only for up to 10 days 
TABLE II—Frequency of side effects (Total no. 
of cases 40) 
Side effects  No.  % 
I. EXTRAPYRAMIDAL SYMPTOMS 
—Parkinsonism 22 55.0 
—Dystonia 8 20.0 
—Akathesia 11 27.5 
II. PSYCHOLOGICAL SYMPTOMS 
—Anxiety 13 32.5 
—Drowsiness 9 23.5 
—Depression 4 10.0 
III. MISCELLANIOUS SYMPTOMS 
—Weight gain 7 17.5 
—Loss of appetite 5 12.5 
—Impotence 2 5.0 
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following injection. Psychological symptoms 
occurred in form of anxiety (13, 32.5%), 
drowsiness (9, 23.6%) and depression (4, 
10.0%). Anxiety and depression were mild 
and could be managed with diazepam 
and imipramine respectively. Drowsiness, 
though persistent, was rather inconsequen-
tial, weighed against the improvement in 
psychotic symptoms. Some other side effects 
which the patients attributed to the drug 
were impotence (2, 5.0%), loss of appetite 
(5, 12.5%) and weight gain (7, 17.5%). 
These again did not bother the patients 
much and could be ignored. 
COMMENTS 
The treatment of chronic schizophrenia 
still remains far from satisfactory. The 
mainstay of management are phenothiazines 
but ensuring that the patient takes his 
medication regularly is difficult. 
Fluphenazine decanoate would appear 
to be immensely useful in such cases. Its 
long action, relatively low cost and certain 
administration make it perhaps the most 
suitable therapy in chronic schizophrenia. 
The treatment was effective in nearly two 
thirds of the cases. This is an impressive 
figure in view of the fact that only chronic 
and rather refractory cases were included 
in the trial. 
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